Biogen Raises Annual Guidance Despite Q3 Earning Impacted By Biosimilar Competition

  • Biogen Inc BIIB posted Q3 sales of $2.51 billion, beating the consensus of $2.47 billion, down 10% Y/Y and 8% at constant currency (CC).
  • Multiple sclerosis revenue, including royalties on sales of Ocrevus, of $1.62 billion decreased by 11% (down 9% CC).
  • Spinraza's revenue of $431 million decreased by 3% at actual currency (increased by 2% at CC).
  • Aduhelm generated sales of $1.6 million in Q3, compared to $0.3 million a year ago.
  • Biosimilars' revenue of $188 million decreased by 7% versus the prior year at actual currency and increased by 4% at constant currency.
  • Multiple sclerosis drug Tysabri sales are down 3.3% to $505.5 million.
  • Adjusted EPS of $4.77 came above the consensus of $4.16.
  • Guidance: Biogen raised FY22 sales guidance to $10-$10.15 billion, up from prior guidance of $9.9-$10.1 billion and the consensus of $10.01 billion.
  • The company expects adjusted EPS of 16.50-$17.15, up from $15.25-$16.75 compared to the consensus of $16.49.
  • The increase in guidance is driven primarily by better-than-expected topline performance and continued cost management.
  • The guidance assumes continued declines in Rituxan revenue due to biosimilar competition and a continued erosion of Tecfidera revenue due to generic entry.
  • Price Action: BIIB shares are down 0.77% at $272.50 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!